GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (TSE:4875) » Definitions » Valuation Rank

MediciNova (TSE:4875) Valuation Rank


View and export this data going back to 2005. Start your Free Trial

What is MediciNova Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

MediciNova Valuation Rank Related Terms

Thank you for viewing the detailed overview of MediciNova's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

MediciNova (TSE:4875) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (TSE:4875) » Definitions » Valuation Rank
Comparable Companies
CLGN CRIS CVM RLYB IKNA VTVT LTRN AFMD AVRO CKPT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
MNOV:USA
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
Website
https://www.medicinova.com
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.